Immunic Inc (NAS:IMUX)

Q3 2024 Immunic Inc Earnings Call Transcript

Nov 7, 2024 / 01:00 PM GMT

Release Date Price: $11.8

Transcript 10-Q8-K

Key Points

Positve

Immunic Inc (IMUX) strengthened its management team with the addition of experienced executives, enhancing its leadership capabilities.
The company achieved a positive outcome in the interim analysis of its phase three ensure program for relapsing multiple sclerosis, indicating progress in clinical trials.
Immunic Inc (IMUX) presented compelling data at the EAMS Congress, showcasing the potential of its drug candidate, vlu calcium, in treating multiple sclerosis.
The company has a strong cash position, with $59.1 million in cash and cash equivalents, expected to fund operations into the third quarter of 2025.
Immunic Inc (IMUX) is actively pursuing partnerships with global and regional pharmaceutical companies, indicating potential for strategic collaborations.

Negative

Research and development expenses increased to $21.4 million for the quarter, reflecting higher external development costs.
The company reported a net loss of approximately $24.4 million for the quarter, indicating ongoing financial challenges.
There is uncertainty regarding the speed of recruitment and data availability for the investigator-sponsored post-COVID trial in Germany.
The company faces significant competition in the multiple sclerosis market, with over 20 approved therapies already available.
Immunic Inc (IMUX) has not yet secured a partnership for non-dilutive cash raises, which could impact future funding opportunities.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IMUX.OQ - Immunic Inc
Q3 2024 Immunic Inc Earnings Call
Nov 07, 2024 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to Munichs third quarter, 2024 earnings call. My name is Jessica Breu, Vice President, Investor Relations and Communications at Munich. I will also be the moderator today. Speaking on the call are Dr Daniel Fitt, our Chief Executive Officer, Glenn Wle, our Chief Financial Officer, as well as Jason Tardio, our President and Chief Operating Officer. Please note that all participants will be in listen-only mode and this event is being recorded after today's presentation. There will be an opportunity to ask questions if you join the webcast via the Zoom platform. There are two ways to submit questions. You can submit your questions in writing via the Q&A tool of the Zoom portal or if you would like to speak with us directly,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.